It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The majority of proteins in mammalian cells are modified by covalent attachment of an acetyl-group to the N-terminus (Nt-acetylation). Paradoxically, Nt-acetylation has been suggested to inhibit as well as to promote substrate degradation. Contrasting these findings, proteome-wide stability measurements failed to detect any correlation between Nt-acetylation status and protein stability. Accordingly, by analysis of protein stability datasets, we found that predicted Nt-acetylation positively correlates with protein stability in case of GFP, but this correlation does not hold for the entire proteome. To further resolve this conundrum, we systematically changed the Nt-acetylation and ubiquitination status of model substrates and assessed their stability. For wild-type Bcl-B, which is heavily modified by proteasome-targeting lysine ubiquitination, Nt-acetylation did not correlate with protein stability. For a lysine-less Bcl-B mutant, however, Nt-acetylation correlated with increased protein stability, likely due to prohibition of ubiquitin conjugation to the acetylated N-terminus. In case of GFP, Nt-acetylation correlated with increased protein stability, as predicted, but our data suggest that Nt-acetylation does not affect GFP ubiquitination. Similarly, in case of the naturally lysine-less protein p16, Nt-acetylation correlated with protein stability, regardless of ubiquitination on its N-terminus or on an introduced lysine residue. A direct effect of Nt-acetylation on p16 stability was supported by studies in NatB-deficient cells. Together, our studies argue that Nt-acetylation can stabilize proteins in human cells in a substrate-specific manner, by competition with N-terminal ubiquitination, but also by other mechanisms that are independent of protein ubiquitination status.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Leiden University Medical Center, Department of Human Genetics, Leiden, the Netherlands (GRID:grid.10419.3d) (ISNI:0000000089452978); The Netherlands Cancer Institute, Division of Tumor Biology and Immunology, Amsterdam, the Netherlands (GRID:grid.430814.a) (ISNI:0000 0001 0674 1393); University Medical Center Groningen, Department of Medical Oncology, Groningen, the Netherlands (GRID:grid.4494.d) (ISNI:0000 0000 9558 4598)
2 The Netherlands Cancer Institute, Division of Tumor Biology and Immunology, Amsterdam, the Netherlands (GRID:grid.430814.a) (ISNI:0000 0001 0674 1393); Leiden University Medical Center, Department of Immunology and Oncode Institute, Leiden, the Netherlands (GRID:grid.10419.3d) (ISNI:0000000089452978)
3 The Netherlands Cancer Institute, Division of Tumor Biology and Immunology, Amsterdam, the Netherlands (GRID:grid.430814.a) (ISNI:0000 0001 0674 1393)
4 Leiden University Medical Center, Center for Proteomics and Metabolomics, Leiden, the Netherlands (GRID:grid.10419.3d) (ISNI:0000000089452978)
5 The Netherlands Cancer Institute, Division of Tumor Biology and Immunology, Amsterdam, the Netherlands (GRID:grid.430814.a) (ISNI:0000 0001 0674 1393); Leiden Academic Centre for Drug Research, Leiden, the Netherlands (GRID:grid.5132.5) (ISNI:0000 0001 2312 1970)




